medigraphic.com

1999, Number 5

<< Back Next >>

Enf Infec Microbiol 1999; 19 (5)

Antimicrobial resistance in enterococci: Clinical implications

Esparza AS, Morfín OR, Rodríguez NE

Language: Spanish
References: 82
Page: 227-235
PDF size: 65.63 Kb.


ABSTRACT

The appearance of multiresistant enterococci represent to therapeutic challenge. During the last decade Enterococcus species have developed high-level gentamicin resistance, beta-lactamase production, vamcomycin and teicoplanin resistance, and high-level ampicillin resistance. The enterococci have become common nosocomial pathogens and problematic community pathogens. Enterococcus like E. faecium and E. faecalis are two of the bacteria that have developed bacterial resistance to almost all available antimicrobial agents. Enterococcus has joined methicillin-resistant Staphylococcus, penicillinresistant Pneumococcus, vancomycin-resistant coagulase- negative Staphylococcus, and vancomycin-resistant S. aureus to the new gram-positive problem bacteria, similar to the gram-negative preponderance in the 1970s. The emergence of transferable multiresistance in grampositive cocci like Enterococcus demands better laboratory methods for its detection and a complete adherence to the recommendations for preventing the spread of resistance in bacteria that frequently cause human infections.


REFERENCES

  1. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev 1990;3:46-65.

  2. Sherman JM. The Streptococci. Bacteriol Rev 1937;1:3-97.

  3. Moellering RC Jr, Wennersten C, Medrek T, Weinberg HN. Prevalence of high-level resistance to aminoglycosides in clinical isolates of Enterococci. Antimicrob Agents Chemother 1970;1:335-40.

  4. Moellering RC Jr, Korzeniowski OM, Sande MA, Wennersten CB. Species-specific resistance to antimicrobial synergism in Streptococcus faecium and Streptococcus faecalis. J Infect Dis 1979;140:203-8.

  5. Eliopoulos GM, Wennersten C, Moellering RC Jr. Resistance to beta-lactam antibiotics in Streptococcus faecium. Antimicrob Agents Chemother 1982;22:295-301.

  6. Sapico FL, Canawati HN, Ginunas VJ, Gilmore DS, Montgomerie JZ, Tuddenham WJ, et al. Enterococci highly resistant to penicillin and ampicillin: An emerging clinical problem? J Clin Microbiol 1989;27:2091-5.

  7. Oster SE, Chirurgi VA, Goldberg AA, Aiken C, McCabe RE. Ampicillin-resistant enterococcal species in an acute-care hospital. Antimicrob Agents Chemother 1990;34:1821-3.

  8. Bush LM, Calmon J, Cherney CL, Wendeler M, Pitsakis P, Poupard J, et al. High-level penicillin resistance among clinical isolates of Enterococci. Ann Intern Med 1989;110:515-20.

  9. Grayson ML, Eliopoulos GM, Wennersten CB, Ruoff KL, De Girolami PC, Ferraro MJ, et al. Increasing resistance to blactam antibiotics among clinical isolates of Enterococcus faecium: A 22-year review at one Institution. Antimicrob Agents Chemother 1991;35:2180-4.

  10. Courvalin P. Resistance of Enterococci to glycopeptides. Antimicrob Agents Chemother 1990;34:2291-6.

  11. Gordon S, Swenson JM, Jill BC, Pigott NE, Facklam RR, Enterococcal Study Group, et al. Antimicrobial susceptibility patterns of common and unusual species of Enterococci causing infections in the United States. J Clin Microbiol 1992;30:2373- 8.

  12. Moellering RC Jr. Emergence of Enterococcus as a significant pathogen. Clin Infect Dis 1992;14:1173-8.

  13. MMWR. Nosocomial Enterococci resistant to vancomycin, United States, 1989-1993. Morb Mortal Wkly Rep 1993;42:597- 9.

  14. Murray BE. Vancomycin-resistant Enterococci. Am J Med 1997;102:284-93.

  15. Murray BE. Diversity among multidrug-resistant Enterococci. Emerg Infect Dis 1998;4:37-47.

  16. Moellering RC Jr. Vancomycin-resistant Enterococci. Clin Infect Dis 1998;26:1196-9.

  17. Moellering RC Jr. Problems with antimicrobial resistance in gram-positive. Clin Infect Dis 1998;26:1177-8.

  18. Zervos MJ, Kaoffman CA, Therasse PM, Bregman AG, Mikesell TS, Schaberg DR. Nosocomial infection by gentamicin-resistant Streptococcus faecalis: An epidemiologic study. Ann Intern Med 1987;106:687-91.

  19. Maki DG, Agger WA. Enterococcal bacteremia: Clinical features, the risk of endocarditis, and management. Medicine (Baltimore) 1988;67:248-69.

  20. Gullberg RM, Homann SR, Phair JP. Enterococcal bacteremia: Analysis of 75 episodes. Rev Infect Dis 1989;11:74-85.

  21. Zervos MJ, Dembinski S, Mikesell T, Schaberg DR. High-level resistance to gentamicin in Streptococcus faecalis: Risk factors and evidence for exogenous acquisition of infection. J Infect Dis 1986;153:1075-83.

  22. Rhinehart E, Smith N, Wennersten C, Gorss E, Freeman J, Eliopoulos GM, et al. Rapid dissemination of beta-lactamase-producing aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant and toddler surgical ward. N Engl J Med 1990;323:1814-8.

  23. Livornese LL Jr, Dias S, Samel C, Romanowski B, Taylor S, May P, et al. Hospital-acquired infection with vancomycinresistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992;117:112-6.

  24. Montecalvo MA, Horowitz H, Gedris C, Carbonaro C, Tenover FC, Issah A, et al. Outbreak of vancomycin, ampicillin, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994;38:1363-7.

  25. Boyce JM, Opal SM, Chow JW, Servos MJ, Potter-Bynoe G, Sherman CB, et al. Outbreak of multi-drug resistant Enterococcus faecium with transferable vanB vancomycin resistance. J Clin Microbiol 1994;32:1148-53.

  26. Boyle JF, Soumakis SA, Rendo A, Herrington JA, Gianarkis DG, Thurberg BE, et al. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycinresistant Enterococci. J Clin Microbiol 1993;31:1280-5.

  27. Handwerger S, Raucher B, Altarac D. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993;16:750-5.

  28. Tokars JI, Satake S, Rimland D, Carson L, Miller ER, Millum E, et al. The prevalence of colonization with vancomycin-resistant Enterococcus at a veterans affairs institution. Infect Control Hosp. Epidemiol 1999;20:171-5.

  29. Megran DW. Enterococcal endocarditis. Clin Infect Dis 1992;15:63-71.

  30. Rice LB, Calderwood SB, Eliopoulos GM, Farber BF, Karchmer AW. Enterococcal endocarditis: A comparison of prosthetic and native valve disease. Rev Infect Dis 1991;13:1-7.

  31. Patterson JE, Sweeney AG, Simms M, Carley N, Mangi R, Sabetta J, et al. An analysis of 110 serious enterococcal infections: Epidemiology, antibiotic susceptibility, and outcome. Medicine (Baltimore) 1995;74:191-200.

  32. Stevenson KB, Murray EW, Sarubbi FA. Enterococcal meningitis: Report of four cases and review. Clin Infect Dis 1994;18:233-9.

  33. Nichols RE, Muzik AC. Enterococcal infections in surgical patients: The mystery continues. Clin Infect Dis 1992;15:72-76.

  34. Noskin GA, Peterson LR, Warren JR. Enterococcus faecium and Enterococcus faecalis bacteremia: Acquisition and outcome. Clin Infect Dis 1995;20:296-301.

  35. Edmond MB, Ober JF, Dawson JD. Vancomycin-resistant enterococcal bacteremia: Natural history and attributable mortality. Clin Infect Dis 1996;23:1234-9.

  36. Linden PK, Pasculle AW, Manez R, Kramer DJ, Fung JJ, Pinna AD, et al. Differences in outcome for patients with bacteremia due to vancomycin-resistant Enterococcus faecium of vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22:663- 70.

  37. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: Risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999;20:318-23.

  38. Wells VD, Wong ES, Murray BE, Coudron PE, Williams DS, Markowitz SM. Infections due to beta-lactamase-producing, high-level gentamicin-resistant Enterococcus faecalis. Ann Intern Med 1992;116:285-97.

  39. Papanicolau GA, Meyer RR, Meyer J, Mendelson MH, Tou W, Emre S, et al. Nosocomial infection with vancomycin-resistant Enterococcus faecium in liver transplant recipients: Risk factors for acquisition and mortality. Clin Infect Dis 1996;23:760-6.

  40. Facklam RR, Collins MD. Identification of Enterococcus species isolated from human infection by a conventional test scheme. J Clin Microbiol 1989;27:731-4.

  41. Swenson JM, Hill BC, Thornsberry C. Problems with the disk diffusion test for detection of vancomycin resistance in Enterococci. J Clin Microbiol 1989;27:2140-2.

  42. Ruoff KL, De la Maza L, Murtagh MJ, Spargo JD, Ferraro MJ. Species identities of Enterococci isolated from clinical specimens. J Clin Microbiol 1990;28:435-7.

  43. Sahm DF, Olsen L. In vitro detection of enterococcal vancomycin resistance. Antimicrob Agents Chemother 1990;34:1846-8.

  44. Tenover FC, Tokars J, Swenson J, Paul S, Spitalny K, Jarvis WR. Ability of clinical laboratories to detect antimicrobial agentresistant enterococci. J Clin Microbiol 1993;31:1695-9.

  45. Swenson JM, Ferraro MJ, Sahm DF, Charache P, Tenover FC. National Committee for Clinical Laboratory Standards Working Group on Enterococci: New vancomycin disk diffusion breakpoints for Enterococci. J Clin Microbiol 1992;30:2525-8.

  46. Swenson JM, Clark NC, Ferraro MJ, Sahm DF, Doern G, Pfaller MA, et al. Development of a standarized screening method for detection of vancomycin-resistant Enterococci. J Clin Microbiol 1994;32:1700-4.

  47. Edberg SC, Hardalo CJ, Kontnick C, Campbell S. Rapid detection of vancomycin-resistant. J Clin Microbiol 1994;32:2182-4.

  48. Satake S, Clarck N, Rmland D, Nolte FS, Tenover FC. Detection of vancomycin-resistant Enterococci in fecal samples by using the polymerase chain reaction. J Clin Microbiol 1997;35:2325- 30.

  49. Moellering RC Jr, Weinberg AN. Studies on antibiotic synergism against enterocci. II. Effect of various antibiotics on the uptake of 14 C-Labelled streptomycin by Enterococci. J Clin Invest 1971;50:2580-4.

  50. Krogstad DJ, Korfhagen TR, Moellering RC Jr, Wennersten C, Swartz MN, Perzynski S, et al. Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis: An explanation for antibiotic synergism. J Clin Invest 1978;62:480- 6.

  51. Moellering RC Jr, Murray BE, Schoenbaum SC, Adler J, Wennersten CB. A novel mechanism of resistance to penicillingentamicin synergism in Streptococcus faecalis. J Infect Dis 1980;141:81-86.

  52. Mederski-Samoraj BD, Murray BE. High-level resistance to gentamicin in clinical isolates of Enterococci. J Infect Dis 1983;147:751-7.

  53. Eliopoulos GM, Farber BF, Murray BE, Wennersten C, Moellering RC Jr. Ribosomal resistance of clinical enterococcal isolates to streptomycin. Antimicrob Agents Chemother 1984;25:398-9.

  54. Murray BE, Mederski-Samoraj B. Transferable b-lactamase: A new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clin Invest 1983;72:1168-71.

  55. Murray BE. b-lactamase-producing Enterococci. Antimicrob Agents Chemother 1992;36:2355-9.

  56. Leclercq R, Deplot E, Doval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319:157-61.

  57. Leclercq R, Derlot E, Weber M, Duval J, Courvalin P. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicirob Agents Chemother 1989;33:10- 15.

  58. Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in Enterococci. Antimicrob Agents Chemother 1993;37:1563-71.

  59. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72:195-8.

  60. Handwerger SD, Pearlman C, Altarac D, McAuliff V. Concomitant high-level vancomycin and penicillin resistant in clinical isolates of Enterococci. Clinical Infect Dis 1992;14:655-61.

  61. Shlaes DM, Etter L, Gutmann L. Synergistic killing of vancomycin-resistant Enterococci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin. Antimicrob Agents Chemother 1991;35:776-9.

  62. Cercenado E, Eliopoulos GM, Wennersten CB, Moellering RC Jr. Abscence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant Enterococci. Antimicrob Agents Chemother 1992;36:2526-8.

  63. Yao JDC, Thauvin-Eliopoulos C, Eliopoulos GM, Moellering RC Jr. Efficacy of teicoplanin in two dosage regimens for experimental endocarditis caused by a b-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother 1990;34:827-30.

  64. Lavoie SR, Wong ES, Coudron PE, Williams DS, Markowitz SM. Comparison of ampicillin-sulbactam with vancomycin for treatment of experimental endocarditis due to a b-lactamaseproducing, highly gentamicin-resistant isolate of Enterococcus faecalis. Antimicrob Agents Chemother 1993;37:1447-51.

  65. Hayden MK, Koening GI, Trenholme GM. Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations. Antimicrob Agents Chemother 1994;38:1225-9.

  66. Hayden MK, Trenholme GM, Schultz JE, Sahm DF. In vitro development of teicoplanin resistant in a vanB Enterococcus faecium isolate. J Infect Dis 1993;167:1224-7.

  67. Gutmann L, Al-Obeid S, Billot-Klein D, Guerrier ML, Collatz E. Synergy and resistance to synergy between b-lactam antibiotics and glicopeptides against glycopeptide-resistant strains of Enterococcus faecium. Antimicrob Agents Chemother 1994;38:824-9.

  68. Coque TM, Arduino RC, Murray BE. High-level resistance to aminoglycosides: Comparison of community and nosocomial fecal isolates of Enterococci. Clin Infect Dis 1995;20:1048-51.

  69. Signoretto C, Boaretti M, Canepari P. Cloning, sequencing and expression in Escherichia coli of the low-affinity penicillinbinding protein of Enterococcus faecalis. FEMS Microbiol Lett 1994;123:99-106.

  70. Fontana R, Aldegheri M, Ligozzi M, López H, Sucari A, Satta G. Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1994;38:1980-3.

  71. Norris A, Reilly JP, Edelstein PH, Brennan PJ, Schuster MG. Chloramphenicol for the treatment of vancomycin-resistantenterococcal infections. Clin Infect Dis 1995;20:1137-44.

  72. Schmit JL. Efficacy of teicoplanin for enterococcal infections: 63 cases and review. Clin Infect Dis 1992;15:302-6

  73. Eliopoulos GM, Wennersten CB, Cole G, Moellering RC Jr. In vitro activities of new oxazolidinone antimicrobial agents against Enterococci. Antimicrob Agents Chemother 1996;40:1745-7.

  74. Moellering RC Jr. A novel antimicrobial agent joins the battle against resistant bacteria. Ann Intern Med 1999;130:155-7.

  75. MMWR. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the hospital infection control practices advisory committee (HICPAC). MMWR Morb Mortal Wkly Rep 1995;44 (No. RR-12):1-13.

  76. Ena J, Dick RW, Jones RN, Wenzel RP. The epidemiology of intravenous vancomycin usage in a university hospital. A 10- year study. JAMA 1993;269:598-602.

  77. Sinkowitz RL, Keyserling HI, Walker TJ, Jarvis WR. The epidemiology of vancomycin usage at a childrens hospital, 1993-1995. J Pediatr Infect Dis 1997;16:485-9.

  78. Jarvis WR. Epidemiology, appropriatness, and cost of vancomycin use. Clin Infect Dis 1998;26:1200-3.

  79. Perl TM. The threat of vancomycin resistance. Am J Med 1999;106 (5a):26s-37s.

  80. Armstrong-Evans M, Litt M, McArthur MA, Willey B, Cann D,Liska S, et al. Control of transmission of vancomycin-resistant Enterococcus faecium in a long-term-care facility. Infect Control Hosp Epidemiol 1999;20:312-7.

  81. Murray BE, Singh KV, Markowitz SM, Lopardo HA, Patterson JE, Zervos MJ, et al. Evidence for clonal spread of a single strain of b-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states. J Infect Dis 1991;163:780-8.

  82. Van den Bogaard AE, Jensen LB, Stobberingh EE. Vancomycinresistant Enterococci in turkeys and farmers. N Engl J Med 1997;337:1558-9.




2020     |     www.medigraphic.com